The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up.
OBJECTIVE
To determine the long-term safety of inactivated hepatitis A virus (HAV) vaccine in men infected with HIV-1.


METHODS
A 1-year prospective case-control study.


METHODS
Targeted primary care and sexually transmitted diseases clinics.


METHODS
Ninety HIV-1-positive patients who participated in an earlier efficacy study of HAV vaccination.


METHODS
Ninety HIV-1-positive men, matched for CD4+ lymphocyte percentage at baseline, who did not receive HAV vaccine.


METHODS
All cases were assigned to receive two intramuscular doses of 1440 enzyme-linked immunosorbent assay units of inactivated HAV vaccine (Havrix) either 1 or 6 months apart.


METHODS
Development of AIDS, survival, and T-cell subsets after 1 year of follow-up.


RESULTS
No significant differences were seen between cases and control for the development of AIDS (10.1 versus 10.7%), deaths (7.3 versus 7.6%) nor for mean decline in circulating CD4+ lymphocyte count (125 versus 123 x 10(6)/1) after 1 year.


CONCLUSIONS
Vaccination against HAV appears to be safe in the longer term for HIV-1-infected men.
Bodsworth
N J
NJ
Academic Unit of Sexual Health Medicine, Sydney Sexual Health Centre, Sydney Hospital, NSW, Australia.
Neilsen
G A
GA
Donovan
B
B
D000328:Adult; D016022:Case-Control Studies; D018450:Disease Progression; D005500:Follow-Up Studies; D015658:HIV Infections / Q000401:mortality / Q000503:physiopathology*; D015497:HIV-1; D022362:Hepatitis A Vaccines; D006801:Humans; D007114:Immunization; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D015164:Vaccines, Inactivated / Q000008:administration & dosage*; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage*
D022362:Hepatitis A Vaccines; D015164:Vaccines, Inactivated; D014761:Viral Hepatitis Vaccines